A stg£3.6m investment by PathXL will see the software company expand its workforce by 32 people in Belfast as it drives sales for its tumour-detection software, TissueMark.
PathXL, which operates in advanced software solutions for digital pathology, is creating 32 highly skilled jobs over the next three years. These positions are to come with salaries well above the Northern Ireland private-sector average, generating almost stg£3m in annual salaries.
Des Speed, chief executive at PathXL, said the ultimate aim is to become world famous for contributing something “really meaningful” to the field of digital pathology.
“This investment will help us to further develop the new TissueMark automated tumour-detection, analysis and identification solution and broaden the exposure of, and interest in, our digital pathology solution concepts,” said Speed.
Invest NI is contributing stg£390,000 to the investment.
“Invest NI’s support will mean we can progress our growth plans at a faster pace and greater scale to develop new products and attract new sales,” Speed added.
The 32 new roles are in areas including software development, account management, software support and testing, operations and project management.
Alastair Hamilton, chief executive of Invest NI, lauded the company’s make-up and service.
“This innovative indigenous company is achieving impressive international success within a niche segment of the pathology market. Its investment reinforces the message that Northern Ireland is an attractive and cost-effective location for knowledge-based business.
“PathXL’s lucrative technology has a multitude of potential applications across the life, health and biological sectors. This investment in market development and workforce will give PathXL the scope to service an expanding market,” Hamilton said.
Invest NI chief executive Alastair Hamilton (left) with Des Speed, chief executive of PathXL. Photo by Harrison Photography
Recruitment image via Shutterstock